Loading organizations...
Founded in 2016 and based in Cardiff, Wales, Ceryx Medical is an early stage, venture-backed medtech company developing bioelectronic medical devices to treat heart failure. The organization's primary product, Cysoni, utilizes biomimetic technology to interpret physiological signals and generate natural responses that mimic the body's functions to restore cardiac rhythm. Following five years of rigorous laboratory testing, the firm is exploring additional therapeutic applications for hypertension, spinal cord injuries, and endocrine disorders such as diabetes. Operating with a small team of one to ten employees and 45 shareholders, the company has raised a total of $6.27 million in equity funding, including a recent $4.7 million financing round. Corporate leadership and scientific development are guided by key personnel including Chief Executive Officer Stuart Plant, Professor Julian Francis Richmond Paton, Charles Richard Taylor, Joseph Caddell, and Ashok Chauhan.
Ceryx Medical has raised $12.0M across 2 funding rounds.
Ceryx Medical has raised $12.0M in total across 2 funding rounds.
Ceryx Medical has raised $12.0M in total across 2 funding rounds.
Ceryx Medical's investors include Parkwalk Advisors, Richard Thompson, Deepbridge Capital.
Ceryx Medical has raised $12.0M across 2 funding rounds. Most recently, it raised $7.0M Series U in June 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2025 | $7M Series U | — | Parkwalk Advisors, Richard Thompson | Announced |
| Apr 1, 2022 | $5M Seed | — | Deepbridge Capital, Parkwalk Advisors, Richard Thompson | Announced |
Ceryx Medical is a UK-based medtech company developing bioelectronic medical devices that mimic the body's natural physiological functions to treat heart failure and potentially other conditions. Its lead product, Cysoni, is a cardiac rhythm management device targeting heart failure with reduced ejection fraction (HFrEF), restoring natural communication between the heart and lungs to improve ejection fraction, cardiac output, and patient quality of life.[1][2][3] The company serves patients with chronic heart failure—a global issue affecting 30 million people and costing healthcare systems £100 billion annually—by addressing limitations of current therapies, which fail 50% of patients within five years.[2][3] Founded in 2016 and headquartered in Cardiff, Wales, Ceryx has raised $21.27M total, including a $15M round in June 2025 to advance clinical trials and a permanent pacemaker, showing strong growth momentum with promising early clinical data post-cardiac surgery.[1][4]
Ceryx Medical was incorporated on February 12, 2016, as a spin-out from research at the Universities of Bristol, Bath, and Auckland, focusing on bioelectronic innovations derived from academic breakthroughs in mimicking neural structures.[4][5] The core idea emerged from addressing disrupted heart-lung communication in heart failure, where damage from heart attacks, infections, or hypertension impairs cardiorespiratory efficiency; founders leveraged analogue circuitry to replicate cell membranes, ion channels, action potentials, and central pattern generators for real-time biological responses.[3] Early traction included seed funding of $6.27M, a 2022 IOP Business Start-Up Award for its revolutionary approach, and progression to advanced preclinical testing, culminating in a $15M raise in 2025 backed by investors like BGF, Parkwalk Advisors, Development Bank of Wales, and BBI.[1][3][4][6]
Ceryx stands out in medtech through its biologically inspired engineering:
Ceryx rides the bioelectronics wave, a trend shifting healthcare from pharmaceuticals to precision neuromodulation devices that restore organ communication, fueled by advances in analogue circuitry and AI-driven biomimicry.[3] Timing aligns with surging heart failure prevalence amid aging populations and post-pandemic cardiovascular strain, where 2% of healthcare budgets fail to curb 50% five-year mortality—market forces favoring non-drug therapies projected to grow as regulators prioritize side-effect-free innovations.[2][4] By pioneering "naturally inspired" pacemakers, Ceryx influences the ecosystem, validating UK medtech spin-outs, attracting VC to Wales/Cardiff hubs, and paving expansion into neurological disorders, potentially disrupting a £100B+ global market.[2][6]
Ceryx is poised to launch its permanent Cysoni pacemaker post-2025 funding, with clinical data driving regulatory approvals and first-in-human trials by 2026-2027, while exploring bioelectronics for neurology.[2][4] Trends like AI-enhanced implants and value-based care will amplify its edge, evolving influence from UK pioneer to global leader in restorative cardiac tech. This positions Ceryx to transform heart failure from progressive decline to manageable recovery, fulfilling its mission for millions.[2]
